A Randomized, Double-Blind, Controlled, Multicenter Dose Verification Clinical Trial to Evaluate the Safety and Effectiveness of GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 88
- 试验地点
- 12
- 主要终点
- Number of Participants That Met the Success Criteria of Radiographic and Clinical Measurements
研究概览
简要总结
GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.
详细描述
This will be a prospective, randomized, double-blinded, controlled, multi-center, dose-verification clinical study in subjects who require surgical intervention to treat a qualifying periodontal defect.
Subjects 25 years and older with advanced periodontal disease in at least one site requiring surgical treatment to correct a bone defect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age of 25 and older
- •Must have read, understood, and signed a consent form
- •Must be able and willing to follow study procedures and instructions
- •Must have undergone thorough scaling and root planing of the target tooth and be expected to demonstrate good plaque control after instruction in oral hygiene
- •The target tooth must exhibit the following:
- •A pocket depth of 7 mm or greater
- •After surgical debridement, 4 mm or greater intrabony defect with at least 1 bony wall
- •Sufficient keratinized tissue to allow complete tissue coverage of the defect
- •Radiographic base of defect at least 3 mm coronal to the apex of the tooth
排除标准
- •Failure to maintain adequate oral hygiene during the screening phase
- •Women of child-bearing potential
- •A history within the last 6 months of HIV, Type IV heart disease, or end-stage renal disease
- •A history of oral cancer or any other cancer (exception: subjects with a history of skin cancers such as squamous and basal carcinoma with end of treatment at least 6 months ago and/or prostate cancer with end of treatment at least 5 years ago may be enrolled)
- •A history within 12 months of previous open flap periodontal surgery on the study tooth.
- •A diagnosis of pre-malignant oral lesion(s)
- •A traumatic occlusion of the target tooth
- •Target "study" tooth exhibiting Grade III mobility
- •Maxillary molars or maxillary first premolar with a prominent mesial concavity
- •Study tooth exhibiting a Class II or greater furcation defect
- •Clinical or radiographic signs of untreated acute or chronic periapical infection at the surgical site, apical pathology, root fracture, severe root irregularities, cemental pearls, cervical enamel projections not easily removed by odontoplasty, untreated carious lesions at the cemento-enamel junction (CEJ) or on the root surface, or restorations with open or otherwise defective margins at or below the CEJ
- •A history within the last 6 months of the daily use of any tobacco products besides cigarettes (smokeless chewing tobacco, pipe or cigar smoking), or of smoking more than 10 cigarettes per day
- •Subjects participating in other clinical trials within 30 days of enrollment
- •Subjects having uncontrolled endocrine-induced diseases (e.g. uncontrolled diabetes mellitus and hyperparathyroidism)
- •Subjects undergoing current therapy with systemic steroids or other drugs that significantly alter bone metabolism
- •Subjects with Localized Juvenile Periodontitis (LJP) sites in the oral cavity
结局指标
主要结局
Number of Participants That Met the Success Criteria of Radiographic and Clinical Measurements
时间窗: 6 months post-surgery
The primary effectiveness endpoint is a composite endpoint that considers radiographic and clinical measurements at six months post-implantation: the amount of linear bone growth (LBG), which is assessed with the use of radiographs, and the regain from baseline of clinical attachment level (∆CAL), which is assessed clinically. Linear bone growth (LBG) in a vertical and horizontal direction is determined radiographically at six months post-implantation. The clinical attachment level (CAL) is the distance from the cemento-enamel junction (CEJ) (or other fixed reference point) generally along the long axis of the tooth to the deepest extent of the periodontal pocket. The success criteria are ΔCAL ≥1.5 mm and LBG ≥1 mm at 6 months after the treatment. Both the ∆CAL and LBG must meet the success criteria for a subject to be considered a success.
次要结局
- Change in Clinical Attachment Level at 6 Months(Baseline and 6 months post-surgery)
- Linear Bone Growth at 6 Months(Baseline and 6 months post-surgery)
- Pocket Depth Change at 6 Months(Baseline and 6 months post-surgery)
- Change in Clinical Attachment Level at 3 Months(Baseline and 3 months post-surgery)
- Percent Bone Fill at 6 Months(Baseline and 6 months post-surgery)
- Pocket Depth Change at 3 Months(Baseline and 3 months post-surgery)
- Change in Gingival Recession at 3 Months(Baseline and 3 months post-surgery)
- Change in Gingival Recession at 6 Months(Baseline and 6 months post-surgery)